Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
NCT03865290
Recruiting
Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Indigestion, Diabetes Mellitus
Register for Updates
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/24/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +233 locations
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
NCT05321368
Recruiting
The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hyp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Choptank Community Health Systems, Denton, Maryland
Conditions: Hypertension, High Blood Pressure, Diabetes, Chronic Kidney Diseases
Register for Updates
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441
Recruiting
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Iowa Hospital, Iowa City, Iowa +14 locations
Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Register for Updates
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
NCT06118515
Recruiting
This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (PK) profile will then be obtained over the next 24 hours, and blood specimens will be shipped immedi... Read More
Gender:
ALL
Ages:
Between 0 days and 90 days
Trial Updated:
04/24/2025
Locations: Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama +9 locations
Conditions: Congenital Cytomegalovirus Infection
Register for Updates
Natural History Study of Kaposi Sarcoma
NCT06375122
Recruiting
Background: Kaposi sarcoma (KS) is a type of tumor caused by the Kaposi sarcoma herpesvirus. KS usually affects the skin, but lesions can also appear in the lymph nodes, lungs and digestive tract. KS is most common in people with compromised immunity, but it also appears in otherwise healthy people. Researchers want to understand more about how KS develops, why it may recur, and how it affects the immune system and organs. Objective: To learn more about the natural history of KS. Eligibility... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Kaposi Sarcoma, HIV
Register for Updates
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786
Recruiting
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma R... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: St. Bernard's Medical Center, Jonesboro, Arkansas +160 locations
Conditions: Colorectal Neoplasms
Register for Updates
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
NCT03865472
Recruiting
This trial studies best dose and how well repetitive transcranial magnetic stimulation (rTMS) works in promoting smoking cessation and preventing relapse in current smokers. rTMS is a form of brain stimulation therapy that controls nerve cell activity, increases blood flow in the brain, and improves cognitive function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cigarette Smoker, Current Every Day Smoker, Current Smoker
Register for Updates
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
NCT04829175
Recruiting
The objective of this post market, clinical registry is to evaluate the performance of the products of the TVT family of products or vaginal vault or uterine prolapse repair (with laparotomic or laparoscopic approach including robotic assisted) using either Gynemesh PS Mesh or Artisyn Mesh in women undergoing surgery for SUI and POP.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: Yale University, New Haven, Connecticut +10 locations
Conditions: Stress Urinary Incontinence, Pelvic Organ Prolapse
Register for Updates
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: IMMUNOe Health and Research Centers, Centennial, Colorado +79 locations
Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Register for Updates
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511
Recruiting
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of California Los Angeles (UCLA), Los Angeles, California +29 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624
Recruiting
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treate... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California +274 locations
Conditions: Prostate Cancer Metastatic
Register for Updates